Factors such as cost, access, and lack of long-term safety data may influence how P-CABs are integrated into practice.

The latest clinical guidelines from the American College of Gastroenterology aim to improve the diagnosis and treatment of ...

Currently, coxib therapy is more expensive than combination therapy using a nonselective NSAID plus a PPI. Conclusions: Compared with combination therapy including a nonselective NSAID and PPI ...

Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

The following is a summary of “Accelerated risk of renal disease progression in pre-ESRD patients with proton pump inhibitors use: a nationwide population-based study,” published in the December 2024 ...

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization ...

Bio, Inc. ("1cBio") an emerging biotech company developing precision medicines for significant unmet needs, and Alesta Pharmaceuticals ("Alesta") a leader in developing first-in-class small molecules ...

and the close temporal relationship between the onset of AIN and the initiation of PPI therapy indicate a causal association. The authors conclude that, in Australia, PPIs are the main cause of ...

What isn’t clear is whether this translates to better outcomes for the patient or whether any of the long-term adverse effects of proton-pump-inhibitor therapy will be reduced. It makes sense ...

A recent study published in the Nature Scientific Reports found a possible connection between gastroesophageal reflux disease ...